No matches
Dermatology

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
Paula Luna, MD
MD
Paula Luna

Related resources

Mast Cells and the Neuroimmune Axis in CSU

Mast Cells and the Neuroimmune Axis in CSU

expert video
UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

expert video
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

videoanimation
What is Early Intervention in AD?

What is Early Intervention in AD?

expert video
Disease Modification in AD

Disease Modification in AD

expert video
Systemic Inflammation in AD – Beyond the Skin

Systemic Inflammation in AD – Beyond the Skin

expert video
Dysbiosis, Skin Infections, and Itch

Dysbiosis, Skin Infections, and Itch

expert video
Skin Barrier Dysfunction in AD

Skin Barrier Dysfunction in AD

expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

expert video
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

expert video
Neuroimmune Axis in Atopic Dermatitis

Neuroimmune Axis in Atopic Dermatitis

expert video
UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

expert video
UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

expert video
UCARE 2023: Neuronal Involvement in CSU

UCARE 2023: Neuronal Involvement in CSU

expert video
UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

expert video
Comorbidities and Disease Burden in CSU

Comorbidities and Disease Burden in CSU

expert video
The Role of Chronic Inflammation in the Pathogenesis of CSU

The Role of Chronic Inflammation in the Pathogenesis of CSU

expert video
Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

expert video
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

expert video
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

expert video
A brief overview of the pathophysiology of PN

A brief overview of the pathophysiology of PN

expert video
Most Burdensome Symptoms Rated by PN Patients

Most Burdensome Symptoms Rated by PN Patients

expert video
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

expert video
Current systemic therapies have been shown to induce remission in a subset of AD patients

Current systemic therapies have been shown to induce remission in a subset of AD patients

expert video
Can advanced systemic therapies modify pathomechanisms in AD?

Can advanced systemic therapies modify pathomechanisms in AD?

expert video
Diagnosis of Bullous Pemphigoid Interactive Patient Case

Diagnosis of Bullous Pemphigoid Interactive Patient Case

interactivity
Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

expert video
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Podcast
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

Podcast
ADVENT On Air | Exploring PN as a Distinct and Unique Disease

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Podcast
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

expert video
Pathophysiology of Blister Formation in Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

expert video
What do we mean by disease control in AD?

What do we mean by disease control in AD?

expert video
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

expert video
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Podcast
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

expert video
What Could Remission Mean in AD?

What Could Remission Mean in AD?

expert video
The Risks of Associated Systemic and Atopic Comorbidities with AD

The Risks of Associated Systemic and Atopic Comorbidities with AD

expert video
Factors Associated With Development of Atopic Comorbidities in AD

Factors Associated With Development of Atopic Comorbidities in AD

expert video
Can Early Intervention Shape the Course of Atopic Dermatitis?

Can Early Intervention Shape the Course of Atopic Dermatitis?

expert video
Association of Younger Age of Onset With Persistence of AD

Association of Younger Age of Onset With Persistence of AD

expert video
CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

Infographic
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Skin Dyspigmentation In Prurigo Nodularis (PN)

Skin Dyspigmentation In Prurigo Nodularis (PN)

interactivity
Explore the Global Burden of Pediatric AD (PEDISTAD)

Explore the Global Burden of Pediatric AD (PEDISTAD)

interactivity
Type 2 Inflammation in AD Manifestations in Skin and Body

Type 2 Inflammation in AD Manifestations in Skin and Body

expert video

Learning objectives

  • Discuss the potential definitions of disease modification in AD
  • Review how AD is associated with an increased risk of multiple non-atopic comorbidities
  • Examine data regarding how early intervention in pediatric patients with AD may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities
Tags
pediatricexpert insightssymposiummechanism of disease
MAT-GLB-2507227 - 1.0 - 12/2025

About this expert

Dermatology

Paula Luna

MD

The Hospital Aleman, Buenos Aires

See author’s profile
Paula Luna, MD

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SingaporeChange country/region